ANI buys 4 products from AstraZeneca

ANI Pharmaceuticals has acquired four potential new drugs from AstraZeneca, the Baudette., Minn.-based company announced recently. The company acquired the new drug applications and U.S. marketing rights to Atacand, Atacand HCT, Arimidex and Casodex for $46.5 million in cash, royalties and sales-based milestones.

“This acquisition complements our brand and generic strategies and further expands and diversifies our commercial portfolio,” ANI president and CEO Arthur Przybyl said. “Importantly, ANI has the capability to manufacture and package all of the products at our containment facility in Baudette, Minn. The addition of these assets will be material to our revenue and EBITDA in 2018, and we plan to provide financial guidance for 2018 at the time of our next regularly scheduled earnings announcement.”

Atacand is indicated to treat hypertension and heart failure; Atacand HCT is indicated to treat hypertension; Arimidex is indicated to treat certain types of breast cancer in postmenopausal women; and Casodex is indicated as a combination therapy in certain types of carcinoma of the prostate, while its 150-mg dosage strength is not yet approved for use. The four drugs collectively generated $19 million for the 12 months ended October 2017, according to IQVIA data.